Alzheimer'
Conditions
Interventions
None listed
Sponsors
National Hospital Organization Kyoto Medical Center
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Alzheimer's disease 1) Outpatients in Kyoto Medical Center 2) Age >= 65 3) Diagnosed with Alzheimer's disease (NINDS-AIREN, DSM-5, ICD-10) 4) Diagnosed by medical specialist of Japan Society for Dementia Research or Japanese Society of Neurology Mild cognitive impairment 1) Outpatients in Kyoto Medical Center 2) Age >= 65 3) Diagnosed with mild cognitive impairment (CDR) 4) Diagnosed by medical specialist of Japan Society for Dementia Research or Japanese Society of Neurology Control 1) Outpatients in Kyoto Medical Center 2) Age >= 65 3) Normal cognitive function 4) Diagnosed by medical specialist of Japan Society for Dementia Research or Japanese Society of Neurology
Exclusion criteria
Exclusion criteria: Alzheimer's disease 1) Diffuse Lewy body disease 2) Frontotemporal dementia 3) The other neurodegenerative disease (progressive supranuclear palsy, corticobasal degeneration etc) 4) Immune-mediated disease (atypische encephalitis etc) in need of steroid therapy 5) Reversible dementia (hypothyroidism, chronic subdural hematoma, Wernicke's encephalopathy, chronic alcoholism etc) 6) Subjects who are judged as unsuitable for the study by the investigator or medical doctor for other reasons Mild cognitive impairment 1) Diffuse Lewy body disease 2) Frontotemporal dementia 3) The other neurodegenerative disease (progressive supranuclear palsy, corticobasal degeneration etc) 4) Immune-mediated disease (atypische encephalitis etc) in need of steroid therapy 5) Reversible dementia (hypothyroidism, chronic subdural hematoma, Wernicke's encephalopathy, chronic alcoholism etc) 6) Subjects who are judged as unsuitable for the study by the investigator or medical doctor for other reasons Control 1) Diagnosed with Alzheimer's disease or mild cognitive impairment 2) The other neurodegenerative disease (progressive supranuclear palsy, corticobasal degeneration etc) 3) Immune-mediated disease (atypische encephalitis etc) in need of steroid therapy 4) Subjects who are judged as unsuitable for the study by the investigator or medical doctor for other reasons
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in cognitive functions | — |
Secondary
| Measure | Time frame |
|---|---|
| DNA methylation, urine analysis, brain imaging, apolipoprotein, blood biochemical parameters, genotype (related to cognitive functions), inflammatory markers | — |
Countries
Japan
Contacts
Public ContactNaoki Sakane
Clinical Research Institute, National Hospital Organization Kyoto Medical Center Department of Preventive Medicine
Outcome results
None listed